Monaco Asset Management SAM Boosts Holdings in Inogen, Inc $INGN

Monaco Asset Management SAM lifted its stake in shares of Inogen, Inc (NASDAQ:INGN) by 6.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 177,594 shares of the medical technology company’s stock after purchasing an additional 10,000 shares during the period. Monaco Asset Management SAM owned about 0.66% of Inogen worth $1,248,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of INGN. CWM LLC boosted its holdings in Inogen by 11.0% in the 2nd quarter. CWM LLC now owns 16,258 shares of the medical technology company’s stock worth $114,000 after buying an additional 1,611 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Inogen by 1.4% in the first quarter. Cubist Systematic Strategies LLC now owns 124,993 shares of the medical technology company’s stock worth $891,000 after acquiring an additional 1,751 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Inogen by 6.4% in the first quarter. American Century Companies Inc. now owns 58,380 shares of the medical technology company’s stock worth $416,000 after acquiring an additional 3,524 shares during the last quarter. Deutsche Bank AG raised its stake in Inogen by 61.6% in the 1st quarter. Deutsche Bank AG now owns 14,856 shares of the medical technology company’s stock valued at $106,000 after purchasing an additional 5,664 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Inogen by 44.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 20,078 shares of the medical technology company’s stock valued at $150,000 after purchasing an additional 6,220 shares in the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a report on Wednesday. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Inogen has an average rating of “Hold” and an average target price of $11.00.

Inogen Stock Performance

NASDAQ:INGN opened at $6.99 on Friday. Inogen, Inc has a one year low of $5.70 and a one year high of $12.91. The stock has a market cap of $189.01 million, a PE ratio of -6.92 and a beta of 1.83. The stock has a 50 day moving average price of $8.34 and a 200 day moving average price of $7.35.

Inogen (NASDAQ:INGN) last issued its earnings results on Wednesday, November 5th. The medical technology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. Inogen had a negative return on equity of 13.21% and a negative net margin of 7.31%.The company had revenue of $92.39 million during the quarter, compared to analysts’ expectations of $92.20 million. Inogen has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts predict that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.